Compare Stocks: CPHI, UTZ, NMRA, and VANI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPHI China Pharma	$0.66 +0.6%	$0.94	$0.38 ▼ $19.19	$28.27M	1.05	1.63 million shs	118,902 shs
NMRA Neumora Therapeutics	$0.50 -9.1%	$1.29	$0.48 ▼ $3.65	$93.93M	2.96	1.70 million shs	2.69 million shs
UTZ Utz Brands	$14.27 +0.0%	$14.19	$6.78 ▼ $14.33	$2.05B	0.72	2.41 million shs	2.06 million shs
VANI Vivani Medical	$1.23 +0.8%	$1.33	$0.92 ▼ $1.92	$110.95M	2.35	337,556 shs	88,201 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPHI China Pharma	-0.61%	-11.74%	-26.24%	-9.05%	-66.27%
NMRA Neumora Therapeutics	-7.75%	-21.77%	-58.65%	-67.07%	-69.10%
UTZ Utz Brands	+0.07%	+0.14%	+0.32%	+72.80%	+16.02%
VANI Vivani Medical	-2.32%	-0.81%	-10.29%	-3.17%	-15.28%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPHI China Pharma	$0.66 +0.6%	$0.94	$0.38 ▼ $19.19	$28.27M	1.05	1.63 million shs	118,902 shs
NMRA Neumora Therapeutics	$0.50 -9.1%	$1.29	$0.48 ▼ $3.65	$93.93M	2.96	1.70 million shs	2.69 million shs
UTZ Utz Brands	$14.27 +0.0%	$14.19	$6.78 ▼ $14.33	$2.05B	0.72	2.41 million shs	2.06 million shs
VANI Vivani Medical	$1.23 +0.8%	$1.33	$0.92 ▼ $1.92	$110.95M	2.35	337,556 shs	88,201 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPHI China Pharma	-0.61%	-11.74%	-26.24%	-9.05%	-66.27%
NMRA Neumora Therapeutics	-7.75%	-21.77%	-58.65%	-67.07%	-69.10%
UTZ Utz Brands	+0.07%	+0.14%	+0.32%	+72.80%	+16.02%
VANI Vivani Medical	-2.32%	-0.81%	-10.29%	-3.17%	-15.28%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CPHI China Pharma	0.00	N/A	N/A	N/A
NMRA Neumora Therapeutics	2.78	Moderate Buy	$6.57	1,214.55% Upside
UTZ Utz Brands	2.00	Hold	$13.39	-6.16% Downside
VANI Vivani Medical	2.25	Hold	$3.75	204.88% Upside

Current Analyst Ratings Breakdown

Latest CPHI, UTZ, NMRA, and VANI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	NMRA Neumora Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/21/2026	UTZ Utz Brands	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/14/2026	NMRA Neumora Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	NMRA Neumora Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/27/2026	UTZ Utz Brands	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/23/2026	UTZ Utz Brands	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$10.00 ➝ $14.25
7/22/2026	UTZ Utz Brands	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$14.25
7/22/2026	UTZ Utz Brands	DA Davidson Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$15.00 ➝ $14.25
7/22/2026	UTZ Utz Brands	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/22/2026	UTZ Utz Brands	DA Davidson Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$15.00 ➝ $14.25
7/21/2026	UTZ Utz Brands	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$14.25

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CPHI China Pharma	$3.91M	7.22	N/A	N/A	$0.70 per share	0.94
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$0.62 per share	N/A
UTZ Utz Brands	$1.44B	1.43	$1.41 per share	10.13	$9.41 per share	1.52
VANI Vivani Medical	N/A	N/A	N/A	N/A	$0.20 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CPHI China Pharma	-$3.08M	-$0.43	N/A	N/A	N/A	-85.56%	-63.93%	-31.42%	N/A
NMRA Neumora Therapeutics	-$236.93M	-$1.23	N/A	N/A	N/A	N/A	-242.28%	-131.32%	11/5/2026 (Estimated)
UTZ Utz Brands	$800K	-$0.33	N/A	16.59	N/A	-2.00%	8.97%	4.32%	10/29/2026 (Estimated)
VANI Vivani Medical	-$26.61M	-$0.35	N/A	N/A	N/A	N/A	-191.05%	-70.91%	11/12/2026 (Estimated)

Latest CPHI, UTZ, NMRA, and VANI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/29/2026	Q3 2026	UTZ Utz Brands	$0.24	N/A	N/A	N/A	$385.05 million	N/A
8/14/2026	Q2 2026	NMRA Neumora Therapeutics	-$0.2401	-$0.23	+$0.0101	-$0.23	N/A	N/A
8/13/2026	Q2 2026	VANI Vivani Medical	-$0.0833	-$0.07	+$0.0133	-$0.07	N/A	N/A
8/5/2026	Q2 2026	UTZ Utz Brands	$0.1847	$0.19	+$0.0053	-$0.11	$374.18 million	$371.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CPHI China Pharma	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A
UTZ Utz Brands	$0.25	1.75%	+18.77%	N/A	3 Years
VANI Vivani Medical	N/A	N/A	N/A	N/A	N/A

Latest CPHI, UTZ, NMRA, and VANI Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
9/10/2026	UTZ Utz Brands	quarterly	$0.0630	1.77%	9/21/2026	9/21/2026	10/1/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CPHI China Pharma	0.22	0.79	0.26
NMRA Neumora Therapeutics	1.19	4.50	4.50
UTZ Utz Brands	0.62	1.06	0.69
VANI Vivani Medical	N/A	3.25	3.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CPHI China Pharma	N/A
NMRA Neumora Therapeutics	47.65%
UTZ Utz Brands	95.97%
VANI Vivani Medical	6.78%

Insider Ownership

Company	Insider Ownership
CPHI China Pharma	6.40%
NMRA Neumora Therapeutics	26.94%
UTZ Utz Brands	12.73%
VANI Vivani Medical	53.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CPHI China Pharma	221	43.02 million	15.92 million	Not Optionable
NMRA Neumora Therapeutics	63	187.90 million	137.28 million	Optionable
UTZ Utz Brands	3,300	143.96 million	125.64 million	Optionable
VANI Vivani Medical	36	90.20 million	42.13 million	Optionable

CPHI, UTZ, NMRA, and VANI Headlines

Recent News About These Companies

Vivani Medical (NASDAQ:VANI) Shares Climb 1.5% - Should You Buy?

October 1 at 2:03 AM | americanbankingnews.com

Vivani Medical Announces Merger Deal Involving Cortigent

September 16, 2026 | tipranks.com

Vivani Medical (NASDAQ:VANI) Trading Down 9.1% - Here's What Happened

September 9, 2026 | marketbeat.com

Vivani Medical to Participate in Upcoming Lake Street and H.C. Wainwright Investor Conferences

September 3, 2026 | quiverquant.comQ

Vivani Medical Announces Participation in Upcoming Investor Conferences

September 3, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Vivani Medical (VANI) and InspireMD (NSPR)

August 20, 2026 | theglobeandmail.com

Vivani Medical Inc U5P

August 19, 2026 | morningstar.comM

Vivani Medical Updates Investors with Regulation FD Presentation

August 17, 2026 | tipranks.com

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

August 13, 2026 | finance.yahoo.com

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

August 13, 2026 | globenewswire.com

Vivani Medical Completes Enrollment, Dosing in Phase 1 SLIM-1 Trial

August 6, 2026 | finance.yahoo.com

ClearOne (CLRO) stock soars over 98% after hours: Here's what you need to know

August 6, 2026 | msn.com

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic ...

August 6, 2026 | finance.yahoo.com

Vivani Completes Enrollment in SLIM-1 Semaglutide Implant Trial

August 6, 2026 | tipranks.com

Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026

July 14, 2026 | globenewswire.com

Next Frontier In Weight Loss? New Implant Looks To Lock In GLP-1 Results

July 14, 2026 | msn.com

The next GLP-1 bet? Implant draws Novo interest

July 13, 2026 | beckershospitalreview.comB

Vivani Medical

July 13, 2026 | fool.com

Weight-loss implant could one day replace Ozempic injections

July 12, 2026 | msn.com

Novo Nordisk (CPSE:NOVO B) Could Be 13% Overvalued Following Its Vivani Deal

July 9, 2026 | finance.yahoo.com

Vivani Medical signs agreement with Novo Nordisk to evaluate NPM-139

July 9, 2026 | pharmabiz.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPHI, UTZ, NMRA, and VANI Company Descriptions

China Pharma NYSE:CPHI

$0.66 +0.00 (+0.61%)

Closing price 04:00 PM Eastern

Extended Trading

$0.65 -0.01 (-1.22%)

As of 06:10 PM Eastern

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.

Neumora Therapeutics NASDAQ:NMRA

$0.50 -0.05 (-9.11%)

Closing price 04:00 PM Eastern

Extended Trading

$0.50 0.00 (-0.38%)

As of 06:16 PM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Utz Brands NYSE:UTZ

$14.26 +0.01 (+0.04%)

Closing price 03:59 PM Eastern

Extended Trading

$14.26 0.00 (0.00%)

As of 05:44 PM Eastern

Utz Brands, Inc. engages in manufacture, marketing, and distribution of snack foods. It offers a range of salty snacks, including salty snacks, including potato chips, tortilla chips, pretzels, cheese snacks, pork skins, veggie snacks, pub/party mixes, tortilla chips, salsa and dips, ready-to-eat popcorn, and other snacks under the Utz, Zapp's, ON THE BORDER, Golden Flake, Boulder Canyon, Hawaiian, TORTIYAHS!, etc. The company sells its products to wholesale and other distributors, grocery stores, convenience and drug stores, discount stores, mass merchandisers, membership club stores, hard discounters, and specialty and e-commerce retailers. Utz Brands, Inc. was founded in 1921 and is headquartered in Hanover, Pennsylvania.

Vivani Medical NASDAQ:VANI

$1.23 +0.01 (+0.82%)

Closing price 04:00 PM Eastern

Extended Trading

$1.24 +0.01 (+0.41%)

As of 04:53 PM Eastern

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CPHI, UTZ, NMRA, and VANI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CPHI, UTZ, NMRA, and VANI Earnings

Compare Dividends

Latest CPHI, UTZ, NMRA, and VANI Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CPHI, UTZ, NMRA, and VANI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPHI, UTZ, NMRA, and VANI Company Descriptions

China Pharma NYSE:CPHI

Neumora Therapeutics NASDAQ:NMRA

Utz Brands NYSE:UTZ

Vivani Medical NASDAQ:VANI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CPHI, UTZ, NMRA, and VANI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CPHI, UTZ, NMRA, and VANI Earnings

Compare Dividends

Latest CPHI, UTZ, NMRA, and VANI Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CPHI, UTZ, NMRA, and VANI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPHI, UTZ, NMRA, and VANI Company Descriptions

China Pharma NYSE:CPHI

Neumora Therapeutics NASDAQ:NMRA

Utz Brands NYSE:UTZ

Vivani Medical NASDAQ:VANI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools